variou
fluorodeoxyribonucleosid
evalu
antivir
activ
influenza
viru
infect
vitro
vivo
among
potent
inhibitor
inhibit
variou
strain
low
highli
pathogen
avian
influenza
virus
pandem
virus
oseltamivirresist
pandem
viru
season
influenza
virus
influenza
b
mdck
cell
inhibitori
concentr
rang
determin
viru
yield
reduct
assay
test
efficaci
balbc
mice
infect
lethal
dose
highli
pathogen
influenza
viru
mgkgd
administ
intraperiton
ip
twice
day
begin
h
viru
exposur
significantli
promot
surviv
surviv
infect
mice
equal
efficaci
treatment
regimen
mice
treat
mgkgday
bid
begin
h
viru
exposur
dose
mice
protect
death
due
viru
infect
respect
lung
harvest
treat
mice
day
four
infect
display
littl
surfac
patholog
histopatholog
lung
weight
lower
mgkg
dose
reduc
lung
viru
titer
although
significantli
compar
placebo
control
dose
well
toler
uninfect
mice
could
also
administ
late
h
post
viru
exposur
still
significantli
protect
mice
lethal
effect
viru
infect
fluorodeoxyribonucleosid
test
mous
model
toxic
higher
dose
inhibitori
lower
dose
final
activ
mous
model
also
activ
pandem
influenza
infect
model
mice
given
mgkgd
bid
begin
h
viru
exposur
also
significantli
enhanc
surviv
mice
similar
result
obtain
infect
model
use
similar
dose
regimen
p
given
demonstr
vitro
vivo
inhibit
avian
influenza
viru
replic
may
qualifi
lead
compound
develop
agent
treat
influenza
viru
infect
impact
influenza
infect
felt
global
year
caus
appar
diseas
approxim
world
popul
moscona
human
influenza
caus
varieti
infect
rang
acut
lower
respiratori
diseas
culmin
acut
respiratori
distress
syndrom
ard
mild
selflimit
febril
ill
http
wwwcdcgovfluaviangeninfofactshtm
season
influenza
pandem
influenza
virus
potenti
caus
pandem
diseas
period
associ
high
mortal
rate
addit
great
concern
highli
pathogen
avian
influenza
virus
infect
caus
inordin
amount
lethal
diseas
human
could
evolv
pose
pandem
risk
kwon
et
al
usual
avian
influenza
viru
refer
influenza
virus
caus
sever
epidem
infect
bird
although
sever
lethal
infect
virus
occur
human
risk
infect
human
highli
pathogen
avian
influenza
virus
gener
low
virus
readili
transmiss
human
bird
infect
uninfect
human
kwon
et
al
howev
viru
lethal
human
mortal
rate
approach
http
wwwwhointcsrdiseaseavianinfluenzacountryen
thu
make
viru
extrem
concern
virus
endem
asia
spread
europ
america
http
wwwwhointcsrdiseaseavianinfluenzacountryen
human
influenza
infect
first
recogn
viru
infect
peopl
hong
kong
caus
death
center
diseas
control
prevent
claa
et
al
suarez
et
al
almost
case
avian
influenza
infect
human
result
contact
infect
chicken
duck
surfac
contamin
secretionexcret
infect
bird
http
wwwcdcgovfluaviangeninfofactshtm
march
human
case
diagnos
around
world
half
infect
die
result
viru
http
wwwwhointcsrdiseaseavianinfluenzacountryen
center
diseas
control
prevent
cdc
anticip
case
hospit
death
associ
viru
popul
littl
effect
protect
immun
viru
strain
http
wwwcdcgovfluaviangeninfofactshtm
although
vaccin
primari
strategi
prevent
influenza
infect
vaccin
ineffect
rapidli
emerg
mutant
viral
antigen
veriti
et
al
vaccin
product
current
method
carri
speed
requir
halt
progress
new
influenza
viru
strain
hayden
although
recent
experiment
pandem
influenza
viru
vaccin
candid
rapidli
develop
use
synthet
dna
approach
includ
sitedirect
mutagenesi
dna
encod
relat
viru
strain
rapid
gener
viru
use
synthet
dna
clone
plasmid
vector
veriti
et
al
addit
vaccin
specif
newli
aris
strain
requir
sever
month
prepar
although
develop
vaccin
influenza
way
number
year
none
yet
approv
use
unit
state
http
wwwcdcgovfluaviangeninfofactshtm
effort
intensifi
recent
year
understand
pathogenesi
influenza
infect
develop
antivir
therapi
treat
season
pandem
well
influenza
diseas
four
antiinfluenza
drug
approv
use
unit
state
ion
channel
inhibitor
amantadin
rimantadin
influenza
viru
neuraminidas
na
inhibitor
oseltamivir
zanamivir
preziosi
studi
indic
mani
avian
influenza
virus
resist
amantadin
rimantadin
trampuz
et
al
virus
gene
contain
mutat
associ
resist
puthavathana
et
al
oseltamivir
tamiflu
wide
use
effect
treatment
strain
influenza
addit
ivadminist
peramivir
approv
unit
state
food
drug
administr
emerg
use
hernandez
et
al
oral
administ
directli
target
site
infect
respiratori
tract
howev
exist
antivir
drug
oseltamivir
zanamivir
seem
inhibit
avian
virus
although
inhibit
case
modest
concern
develop
resist
two
drug
routin
use
treat
infect
govorkova
et
al
leneva
et
al
naughtin
et
al
therefor
great
need
develop
easili
synthesiz
altern
potent
antiinfluenza
drug
combat
human
diseas
caus
highli
pathogen
avian
influenza
virus
hpaiv
address
potenti
need
treat
newli
emerg
drugresist
strain
influenza
virus
aoki
et
al
thorlund
et
al
ujik
et
al
regard
promis
experiment
antiinfluenza
drug
favipiravir
shown
inhibit
varieti
influenza
virus
includ
hpaiv
furuta
et
al
sidwel
et
al
antivir
effect
first
report
herp
viru
pseudorabi
viru
equin
abort
viru
wohlrab
et
al
bajramov
et
al
report
exhibit
potent
antivir
activ
borna
diseas
viru
bdv
bajramov
et
al
stuyver
et
al
demonstr
potent
inhibitor
hepat
c
viru
rna
replicon
cell
stuyver
et
al
suggest
shown
affect
viral
target
cellular
target
hand
skoog
et
al
first
report
inhibitor
dna
replic
mammalian
cell
bjursel
et
al
confirm
block
initi
polyoma
viru
dna
synthesi
also
previous
report
inhibit
hiv
bianchi
et
al
giacca
et
al
addit
found
inhibit
thymidin
kinasedefici
tk
mutant
strain
herp
simplex
viru
hsv
de
clercq
et
al
also
specif
investig
potenti
antivir
agent
seri
evalu
antiinfluenza
activ
cell
cultur
mous
pneumonia
model
tuttl
et
al
mani
found
inhibitor
influenza
compound
test
mdck
cell
potent
inhibitor
influenza
viru
replic
ec
valu
respect
potent
inhibitor
influenza
viru
replic
chicken
embryo
fibroblast
compound
found
equal
inhibitori
influenza
viru
replic
human
tracheal
cultur
found
broadspectrum
vitro
inhibitor
influenza
virus
inhibit
influenza
influenza
b
virus
nearli
equal
found
select
inhibit
influenza
transcriptas
complex
less
inhibitori
transcriptas
complex
isol
partial
resist
influenza
viru
tisdal
et
al
anoth
studi
shown
differ
vitro
antiinfluenza
viru
activ
twenti
purin
fluororibonucleosid
base
amount
nucleosid
triphosph
compound
gener
mdck
cell
cef
cell
vivo
mgkg
deliv
oral
h
viru
exposur
shown
reduc
lung
viru
titer
treatment
effect
amantadin
ribavirin
protect
mice
death
administ
subcutan
twice
day
day
begin
h
prior
exposur
viru
studi
vitro
activ
reduc
viru
lung
titer
mous
model
h
post
viru
exposur
ferret
mgkg
given
h
viru
exposur
reduc
viru
replic
lung
amelior
fever
nasal
inflamm
jakeman
et
al
thu
may
warrant
evalu
influenza
viru
inhibit
vitro
vivo
especi
highli
pathogen
avian
influenza
virus
strain
current
studi
test
effect
fluorocytidin
analog
inhibit
highli
pathogen
avian
influenza
virus
well
influenza
virus
vitro
sever
inhibitori
analog
test
efficaci
balbc
mice
infect
lethal
dose
highli
pathogen
influenza
viru
pandem
viru
na
protein
replic
core
coldadapt
ann
arbor
viru
contain
pa
np
ns
gene
segment
latter
viru
gener
use
revers
genet
ha
gene
genet
modifi
remov
stretch
basic
amino
acid
connect
domain
ha
describ
suguitan
et
al
ainfluenza
influenza
virus
ahong
viru
na
mutat
oseltamivir
resist
cdc
chen
et
al
influenza
b
virus
receiv
cdc
virus
use
cell
cultur
experi
passag
madindarbi
canin
kidney
mdck
cell
american
type
cultur
collect
manassa
va
least
prepar
pool
pool
titrat
mdck
cell
use
cell
grown
mem
contain
fetal
bovin
serum
thermo
fisher
scientif
inc
logan
ut
sodium
bicarbon
antibiot
co
incub
viral
propag
assay
done
mdck
cell
mem
sodium
bicarbon
unit
trypsinml
edtaml
novel
mous
adapt
strain
origin
obtain
elena
govorkova
st
jude
children
research
hospit
memphi
tn
design
influenza
pandem
viru
sj
adapt
mice
natalia
ilyushina
st
jude
children
research
hospit
memphi
tn
influenza
strain
use
studi
first
passag
mdck
cell
grown
embryon
chicken
egg
adapt
mice
sequenti
passag
mous
lung
viru
last
lung
passag
plaqu
purifi
mdck
cell
amplifi
embryon
chicken
egg
viru
amplifi
mdck
cell
prepar
stock
mous
studi
mice
expos
ld
pfu
viru
intranas
rout
ribavirin
provid
z
hong
valeant
pharmaceut
inc
costa
mesa
ca
oseltamivir
purchas
local
pharmaci
test
studi
obtain
chemgen
corpor
wilmington
carbosynth
ltd
compton
berkshir
uk
carbosynth
ltd
compton
berkshir
uk
provid
trilink
biotechnolog
san
francisco
ca
obtain
sigmaaldrich
st
loui
mo
see
figur
structur
prepar
use
vivo
anim
studi
suspend
carboxymethyl
cellulos
cmc
solubil
physiolog
steril
salin
pss
store
use
test
compound
dissolv
dimethyl
sulfoxid
dmso
vitro
studi
dilut
mem
efficaci
test
antivir
activ
determin
vitro
follow
method
inhibit
virusinduc
cytopath
effect
cpe
determin
visual
microscop
examin
cell
increas
uptak
vital
dye
neutral
red
cell
nr
assay
viru
yield
reduct
vyr
assay
method
describ
previous
cytopath
effect
observ
measur
viru
effect
cell
morpholog
may
may
reflect
physiolog
chang
cell
induc
viru
infect
neutral
red
vital
dye
stain
function
lysosom
thu
reflect
physiolog
statu
cell
viru
yield
reduct
assay
measur
effect
compound
amount
viru
releas
cell
thu
one
could
expect
compound
may
profound
effect
one
paramet
measur
one
paramet
measur
describ
eight
onehalf
log
concentr
test
compound
evalu
triplic
well
contain
influenza
virusmdck
cell
standard
placebotr
viru
control
toxic
control
normalmedium
control
includ
assay
vitro
assay
done
mdck
cell
grown
mem
supplement
sodium
bicarbon
unit
trypsinml
edtaml
gentamicinml
ad
antivir
assay
assay
incub
cpe
inhibit
data
express
inhibitori
viral
cpeinhibitori
concentr
ic
cytotox
cellinhibitori
concentr
cc
select
index
si
determin
cc
ic
neutral
red
nr
uptak
assay
perform
describ
kumaki
et
al
briefli
medium
remov
well
plate
neutral
red
nr
ad
well
plate
plate
incub
h
dark
neutral
red
nr
solut
remov
well
well
rins
remain
dye
extract
use
citrat
buffer
ethanol
absorb
nm
read
micropl
reader
opsi
dynex
technolog
chantilli
va
absorb
valu
express
percentag
untreat
control
ic
cc
si
valu
calcul
describ
titer
infecti
viru
produc
supernat
fluid
infect
cell
antivir
cpe
inhibit
assay
determin
previous
describ
score
cpe
test
well
plate
plate
frozen
thaw
sampl
well
one
compound
concentr
test
pool
titer
mdck
cell
infecti
viru
cpe
assay
total
test
concentr
compound
test
titer
viru
product
viru
yield
reduct
ic
valu
compound
determin
linear
regress
analysi
defin
concentr
inhibit
viru
yield
cell
supernat
factor
onelog
ic
use
confirm
result
cpe
inhibitionnr
uptak
assay
specif
pathogenfre
femal
g
balbc
mice
obtain
charl
river
laboratori
wilmington
studi
maintain
wayn
lab
blox
fed
standard
mous
chow
tap
water
ad
libitum
balbc
mice
quarantin
h
prior
use
highli
pathogen
avian
influenza
viru
anim
studi
carri
certifi
biosafeti
level
anim
facil
anim
procedur
compli
guidelin
set
forth
usda
utah
state
univers
institut
anim
care
use
committe
mani
highli
pathogen
avian
influenza
virus
readili
infect
mice
without
adapt
often
caus
lethal
diseas
anim
gubareva
et
al
hatta
et
al
lu
et
al
number
paramet
use
monitor
influenza
viru
infect
mice
common
measur
includ
mean
time
death
arteri
oxygen
satur
declin
lung
patholog
score
lung
weight
chang
host
weight
lung
viru
titer
histopatholog
chang
lung
sidwel
smee
femal
balbc
mice
anesthet
ml
intraperiton
ip
inject
mgkg
ketamin
influenza
viru
pfu
viru
pfu
administ
intranas
volum
ml
group
mice
administ
vari
concentr
per
os
po
ip
twice
day
day
bid
begin
h
viru
exposur
ribavirin
use
posit
control
drug
also
administ
po
ip
h
viru
exposur
depend
experi
fluorocytidin
compound
administ
ip
rout
fifteen
mice
either
treat
po
water
cmc
ip
pss
cmc
h
prior
viru
exposur
twice
day
day
mice
two
group
repres
placebo
control
anim
death
record
day
post
viru
exposur
avian
influenza
virusinocul
mockinfect
mice
weigh
everi
day
clinic
sign
observ
weight
loss
determin
infect
uninfect
group
mice
anim
lost
greater
initi
bodi
weight
human
euthan
co
asphyxi
day
euthan
design
day
death
due
infect
certain
experi
five
mice
group
sacrif
day
viru
exposur
mous
lung
collect
homogen
viru
titer
determin
sampl
assay
triplic
mdck
cell
cytopath
effect
assay
cell
cultur
infecti
dose
valu
calcul
paramet
determin
effect
treatment
includ
prevent
death
day
inhibit
lung
consolid
lung
score
lung
weight
lessen
lung
viru
titer
toxic
control
consist
three
mice
compound
concentr
test
evalu
daili
weight
loss
advers
event
ruffl
fur
lethargi
paralysi
incontin
repetit
circular
motion
aggress
fluorocytidin
test
efficaci
mice
dose
rang
find
experi
usual
done
determin
maximum
toler
concentr
five
mice
use
per
treatment
group
weight
taken
prior
start
treatment
anim
observ
overt
sign
toxic
death
day
advers
event
observ
made
includ
ruffl
fur
lethargi
paralysi
incontin
repetit
circular
motion
aggress
mice
also
weigh
everi
day
h
prior
viru
infect
day
post
viru
exposur
untreat
control
also
includ
studi
evalu
healthi
describ
lung
score
base
surfac
appear
gross
patholog
hemorrhag
lung
lung
assign
score
rang
indic
lung
look
normal
denot
entir
surfac
area
lung
inflam
show
plum
color
lung
discolor
sidwel
et
al
lung
viru
titer
analyz
mice
sacrif
day
post
viru
exposur
lobe
mous
lung
homogen
tissu
fragment
allow
settl
variou
dilut
supernat
fluid
assay
triplic
infecti
viru
mdck
cell
cpe
assay
describ
previous
titer
ccid
valu
calcul
use
reedmuench
method
mice
weigh
group
prior
treatment
everi
day
thereaft
determin
averag
weight
chang
anim
treatment
group
weight
express
group
averag
day
evalu
statist
signific
twoway
analysi
varianc
differ
two
treatment
group
analyz
signific
bonferroni
pairwis
comparison
test
jaccard
et
al
surviv
analys
analyz
use
kaplanmei
graphic
method
logrank
test
lee
wang
signific
differ
among
treatment
group
observ
pairwis
comparison
survivor
curv
placebo
vs
treatment
analyz
gehanbreslowwilcoxon
test
graphpad
mac
rel
signific
adjust
bonferronicorrect
signific
threshold
number
treatment
comparison
done
bland
hazard
ratio
compar
rapidli
group
treat
mice
die
rel
untreat
control
group
mice
determin
mantelhaenszel
test
part
surviv
analysi
program
use
graphpad
mac
mean
day
death
death
caus
diseas
calcul
analyz
kruskalw
test
follow
dunn
posttest
evalu
signific
pairwis
comparison
dunnett
tamhan
live
number
per
total
mice
group
differ
evalu
conting
tabl
analysi
signific
differ
lung
weight
lung
viru
titer
detect
anova
subsequ
pairwis
comparison
made
newmankeul
posttest
signific
differ
lung
score
determin
kruskalw
test
follow
dunn
pairwis
comparison
posttest
first
examin
effect
figur
two
compound
shown
inhibit
rna
virus
inhibit
replic
variou
avian
influenza
virus
mdck
cell
potent
inhibit
hong
viru
ic
valu
visual
assay
valu
neutral
red
uptak
assay
tabl
activ
confirm
viru
yield
reduct
assay
ic
also
inhibit
similar
fashion
nr
nr
vyr
inhibit
independ
cell
cytotox
si
valu
compound
rang
howev
viru
somewhat
less
sensit
inhibit
ic
valu
visual
nr
assay
ic
also
potent
select
inhibit
viru
ic
valu
visual
assay
neutral
red
uptak
assay
si
valu
rang
inhibitori
activ
confirm
viru
yield
reduct
assay
ic
calcul
equal
howev
two
virus
clade
complet
insensit
inhibit
compound
observ
seen
three
differ
experi
examin
effect
fluorodeoxyribonucleosid
inhibit
influenza
viru
replic
see
import
nucleosid
inhibit
viru
replic
tabl
figur
also
evalu
see
azid
group
contribut
significantli
antivir
effect
seen
previous
azidocytidin
analog
shown
inhibit
hepat
c
viru
smith
et
al
hong
virus
modestli
inhibit
figur
ic
valu
rang
activ
slightli
select
viru
inhibit
test
concentr
viru
inhibit
compound
figur
figur
essenti
inhibit
virus
exhibit
strain
specif
inhibit
demonstr
inhibit
viru
two
strain
assum
order
enter
cell
dephosphoryl
becom
triphosph
form
sourc
compound
found
commerci
avail
inhibit
avietnam
strain
potent
ic
valu
averag
three
visual
assay
done
three
neutral
red
uptak
assay
perform
activ
select
si
valu
rang
data
previous
present
appear
consist
inhibit
virus
test
thu
experi
done
describ
spectrum
viru
inhibit
compound
determin
broad
spectrum
antiinfluenza
activ
vitro
sensit
two
hybrid
strain
influenza
express
na
backbon
tabl
addit
difluoro
analog
approv
cancer
therapi
sai
saito
gemcitabin
also
evalu
viru
inhibit
virus
test
potent
sensit
ic
inhibit
among
virus
test
strain
sensit
inhibit
ic
valu
equal
visual
nr
assay
respect
tabl
broadspectrum
inhibit
activ
influenza
virus
also
translat
strong
reduct
viru
yield
almost
virus
ic
valu
rang
strain
tabl
tabl
ic
valu
virus
test
rang
hybrid
virus
express
ha
na
protein
gemcitabin
figur
assay
toxic
detect
cc
valu
rang
visual
assay
neutral
take
assay
nevertheless
inhibitori
activ
virus
overal
select
cytotox
factor
si
valu
rang
activ
discov
visual
neutral
red
assay
confirm
viru
yield
reduct
assay
ic
valu
rang
initi
evalu
efficaci
mous
model
carri
infect
group
mice
lethal
dose
highli
pathogen
influenza
viru
infect
done
anesthet
mice
ip
inject
ketamin
instil
ccid
ml
viru
nare
mice
treat
po
ip
total
mgkg
per
day
twice
day
day
mgkgday
ribavirin
twice
day
day
begin
h
viru
exposur
control
infect
mice
treat
po
water
ip
pss
parallel
placebotr
mice
receiv
calcul
ld
dose
die
expect
fig
po
administr
ip
administr
influenza
virusinfect
mice
treat
dose
per
os
rout
administr
protect
mortal
due
viru
infect
fig
although
ribavirin
treatment
deliv
per
os
mgkgd
significantli
protect
mice
death
p
lack
protect
death
mice
treat
per
os
rout
correl
data
show
per
os
deliv
treatment
amelior
weight
loss
either
fig
hand
ribavirintr
mice
major
surviv
effect
viru
infect
lost
much
less
weight
contrast
data
mice
treat
po
rout
virusinfect
mice
treat
mgkgday
ribavirin
mgkgd
ip
rout
partial
significantli
protect
death
compar
infect
mice
receiv
placebo
ip
rout
fig
p
protect
death
also
signific
mice
treat
ribavirin
po
rout
p
mice
receiv
treatment
lose
less
weight
mice
treat
placebo
fig
surviv
mice
includ
receiv
ribavirin
went
gain
weight
end
experi
nearli
equal
origin
bodi
weight
record
initi
studi
fig
followup
studi
mice
administ
higher
dose
mgkg
use
ip
treatment
regimen
describ
previous
shown
mgkg
dose
significantli
protect
mice
death
treat
mice
surviv
experi
fig
similarli
efficaci
compar
dose
suggest
maxim
protect
effect
achiev
dose
mice
surviv
infect
treat
mgkgd
higher
dose
littl
toxic
observ
except
tendenc
littl
weight
loss
data
shown
viru
lung
titer
day
post
infect
somewhat
lower
mice
receiv
mgkgd
treatment
compar
mice
receiv
placebo
mgkg
tabl
although
differ
statist
signific
ribavirin
treatment
result
signific
reduct
almost
viru
titer
p
compar
lung
viru
titer
placebotr
mice
gross
patholog
mild
day
mice
yet
lessen
lung
weight
presum
reflect
less
lung
edema
mice
treat
mgkgd
signific
reduct
lung
weight
mice
treat
mgkgd
ribavirin
mgkgd
p
p
respect
microscop
inspect
lung
tissu
day
viru
exposur
histolog
stain
reveal
littl
pathogenesi
would
expect
earli
infect
even
though
peak
viru
lung
titer
attain
time
infect
sidwel
et
al
subsequ
experi
found
addit
benefit
treat
mgkgd
contrari
dose
detriment
weight
recoveri
mice
mice
surviv
infect
data
shown
thu
mgkgd
dose
given
bid
effect
dose
regimen
protect
mice
death
due
viru
infect
appear
maximum
toler
effect
dose
next
experi
determin
efficaci
could
achiev
less
frequent
frequent
dose
group
mice
administ
ip
mgkgday
ip
day
bid
tid
qd
begin
h
viru
exposur
addit
mice
treat
mgkgd
ip
bid
begin
variou
time
post
viru
exposur
experi
placebotr
mice
receiv
calcul
ld
dose
die
expect
fig
number
dose
regimen
provid
signific
protect
death
compar
vehicl
although
signific
differ
treatment
regimen
mgkgday
given
twice
day
day
begin
h
viru
exposur
regimen
greatest
number
mice
surviv
infect
fig
tabl
live
pertot
ratio
p
appear
treatment
promot
total
surviv
also
indic
mice
treatment
group
less
like
die
mice
treat
placebo
tabl
hazard
ratio
addit
treat
infect
mice
h
post
viru
exposur
significantli
protect
mice
lethal
effect
viru
challeng
p
hazard
ratio
treatment
drug
administ
h
infect
prolong
day
death
point
day
viru
exposur
tabl
mean
median
day
death
day
largest
number
mice
die
see
median
day
death
significantli
protect
mice
death
p
treatment
regimen
evalu
design
examin
effect
vari
frequenc
treatment
begin
treatment
h
bid
day
provid
mice
total
dose
per
day
previous
shown
provid
protect
exampl
treatment
regimen
involv
administ
mgkgday
day
day
significantli
efficaci
protect
mice
lethal
viru
infect
contrast
given
day
afford
mice
signific
protect
death
compar
mice
vehicl
control
group
despit
reach
protect
p
howev
mice
receiv
dose
regimen
involv
administr
drug
three
time
day
significantli
protect
death
regardless
dose
use
mgkg
mgkg
p
latter
treatment
regimen
effect
treat
mg
kgday
given
twice
day
day
vitro
screen
variou
fluorocytidin
found
move
fluoro
group
posit
nucleosid
base
viru
even
potent
inhibit
although
hpaiv
strain
test
sensit
inhibit
tabl
addit
ad
anoth
fluoro
group
posit
sugar
get
gemcitabin
also
greatli
enhanc
potenc
influenza
virus
tabl
although
assay
gemcitabin
cytotox
thu
evalu
gemcitabin
carri
infect
group
mice
lethal
dose
highli
pathogen
influenza
viru
infect
treatment
compound
ip
rout
sinc
rout
administr
found
efficaci
way
deliv
mice
treat
ip
mgkgd
cmc
twice
day
day
begin
h
viru
exposur
control
infect
mice
treat
ip
cmc
parallel
influenza
virusinfect
mice
receiv
ip
rout
shield
death
compar
infect
mice
receiv
cmc
fig
mice
treat
mgkg
dose
die
greater
number
untreat
mice
p
fact
untreat
mice
consider
toxic
form
sever
weight
loss
mgkgd
dose
death
data
shown
mgkg
dose
although
welltoler
effect
promot
surviv
infect
mice
suggest
structur
enhanc
toxic
lower
efficaci
compar
use
similar
treatment
regimen
maximum
toler
dose
studi
done
gemcitabin
suspicion
dose
similar
dose
use
would
toxic
shown
inde
data
studi
suggest
dose
mgkgd
could
use
without
mice
quickli
succumb
death
data
shown
thu
efficaci
studi
mice
administ
gemcitabin
mgkgd
cmc
bid
begin
h
viru
exposur
although
dose
well
toler
uninfect
mice
data
shown
significantli
effect
protect
mice
lethal
challeng
dose
viru
fig
data
suggest
alter
substitut
sugar
either
move
fluoro
group
posit
nucleosid
base
ad
anoth
fluoro
posit
sugar
result
less
efficaci
toxic
compound
administ
mice
final
evalu
pandem
influenza
viru
determin
also
broadspectrum
inhibitor
influenza
virus
vivo
vitro
use
dose
regimen
describ
initi
evalu
efficaci
viru
administ
mice
h
viru
exposur
mgkgd
bid
fig
mgkg
dose
significantli
protect
mice
lethal
effect
viru
infect
dose
mice
infect
viru
initi
efficaci
studi
addit
mice
mg
dosag
group
almost
time
less
like
die
infect
mice
placebo
treatment
group
tabl
see
hazard
ratio
thu
data
suggest
broad
spectrum
rel
nontox
inhibitor
influenza
virus
vitro
vivo
report
demonstr
inhibitori
broad
spectrum
influenza
influenza
b
virus
includ
three
strain
highli
pathogen
avian
influenza
viru
mdck
cell
inhibitori
concentr
rang
determin
viru
yield
reduct
assay
tabl
found
select
substitut
sugar
moieti
cytidin
nucleosid
specif
addit
second
fluoro
group
posit
move
fluoro
group
posit
nucleosid
enhanc
potenc
inhibit
influenza
virus
vitro
although
ad
second
fluoro
group
posit
might
result
increas
cytotox
vitro
assay
done
overal
gemcitabin
appear
slightli
potent
inhibitor
influenza
viru
replic
assess
viru
yield
reduct
assay
ic
valu
ic
valu
although
cytotox
detect
assay
use
gemcitabin
fluorodeoxyribonucleosid
either
inhibitori
influenza
virus
margin
activ
guanosin
fluorodeoxynucleosid
much
earlier
report
shown
potent
inhibitor
influenza
viru
replic
ec
valu
respect
studi
potent
inhibitor
influenza
viru
replic
chicken
embryo
fibroblast
total
inact
compound
found
equal
inhibitori
influenza
viru
replic
human
tracheal
cultur
jakeman
et
al
base
efficaci
data
cef
cell
investig
report
earlier
studi
chose
pursu
ribonucleosid
anim
test
data
support
previou
find
found
inhibit
influenza
highli
pathogen
avian
influenza
speci
cpe
reduct
assay
day
durat
mdck
cell
ic
respect
potent
two
compound
inhibit
viru
previou
studi
plaqu
reduct
assay
day
durat
mdck
cell
respect
use
potent
two
compound
mdck
cell
studi
studi
studi
done
tisdal
et
al
compound
rel
nontox
current
studi
well
studi
tisdal
et
al
activ
previou
studi
higher
ic
valu
mdck
cell
shown
due
rate
limit
step
triphosph
format
mdck
cell
interestingli
guanosin
nucleosidelik
analog
favipiravir
ribavirin
inhibit
influenza
virus
perhap
viru
transcriptas
complex
seem
like
phosphoryl
triphosph
form
quit
well
mdck
cell
furuta
et
al
suggest
may
well
act
ribonucleosid
sinc
confirm
andribonucleosid
adopt
conform
blandin
et
al
may
assum
conform
thu
act
ribonucleosid
may
actual
act
substrat
influenza
rna
polymeras
complex
alreadi
demonstr
substrat
inhibitor
influenza
polymeras
tisdal
et
al
may
also
inhibit
rna
polymeras
shi
et
al
report
may
also
act
substrat
hcv
rna
polymeras
fluoro
group
group
actual
recogn
hcv
polymeras
shi
et
al
thu
conceiv
might
act
gener
viral
rna
polymeras
inhibitor
altern
may
act
immunomodul
vivo
sinc
shown
cytostat
cell
stuyver
et
al
addit
cytidin
analog
close
relat
gemcitabin
shown
inhibit
ribonucleotid
reductas
shao
et
al
cytidin
synthetas
heinemann
et
al
inhibit
may
also
mechan
inhibit
influenza
viru
infect
lack
protect
toxic
high
dose
may
due
inhibit
host
dna
polymeras
richardson
et
al
examin
efficaci
balbc
mous
model
infect
lethal
dose
highli
pathogen
influenza
viru
dose
regimen
mgkg
administ
intraperiton
h
viru
exposur
twice
day
eight
day
result
surviv
rate
reduct
viru
lung
titer
probabl
edema
lung
associ
viru
pathogenesi
use
mgkgd
nearli
effect
higher
dose
neither
dose
reduc
viru
lung
titer
compar
viru
titer
lung
mice
treat
ribavirin
could
suggest
immunomodul
discuss
may
contribut
efficaci
facilit
surviv
influenzainfect
mice
regimen
almost
equal
efficaci
significantli
inhibit
mortal
mice
due
viru
infect
includ
dose
h
prior
viru
exposur
bid
parcel
mgkgd
dose
three
equal
dose
period
hour
tid
also
efficaci
even
singl
dose
mgkg
given
period
day
significantli
protect
mice
death
due
viru
infect
compar
placebotr
mice
inher
variabl
experi
appar
treatment
group
start
post
infect
provid
numer
better
protect
death
compar
number
death
treatment
group
receiv
compound
start
post
infect
summari
data
suggest
dose
regimen
provid
similar
level
protect
within
variabl
experi
except
mgkg
dose
administ
day
dose
start
infect
provid
signific
benefit
compar
dose
start
infect
also
interest
note
dose
mgkg
tid
versu
qd
administr
dose
provid
similar
level
protect
final
similar
efficaci
influenza
viru
mice
treat
mgkgd
twice
day
day
achiev
attain
mice
infect
highli
pathogen
avian
influenza
viru
mice
use
dose
treatment
regimen
howev
treatment
influenza
viru
mice
mgkgd
twice
day
day
effect
treatment
influenza
ribavirin
mgkgd
use
treatment
regimen
similar
efficaci
may
achiev
mice
treat
mgkgd
dose
closer
molar
equival
ribavirin
use
mgkgd
studi
support
hypothesi
cytidin
nucleosid
analog
particular
cytidin
deoxyribonucleosid
might
repres
good
platform
develop
potent
inhibitor
rna
virus
includ
influenza
virus
thu
studi
might
provid
basi
develop
addit
potent
clinic
use
inhibitor
use
antiinfluenza
agent
includ
highli
pathogen
avian
influenza
virus
also
significantli
enhanc
surviv
mice
infect
pandem
viru
evalu
higher
dose
efficaci
highli
pathogen
influenza
viru
infect
balbc
mice
vehicl
placebo
ribavirin
administ
intraperiton
experiment
group
n
placebo
group
n
cmc
ribavirin
mgkgday
bid
begin
h
rel
viru
exposur
p
mgkg
mgkg
ribavirin
mgkgd
effect
cytidin
analog
replic
highli
pathogen
avian
influenza
virus
mdck
cell
effect
reolic
influenza
virus
mdck
cell
valu
cpe
nr
assay
arithmet
mean
three
independ
experi
vyr
assay
done
one
time
viru
yield
reduct
assay
b
ic
